Juvenile psoriatic arthritis

4 trials 3 recruiting MedDRA PT
4 Registered trials
3 Recruiting
3 Unique sponsors
5 Unique IMPs
4 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 2
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Monoclonal antibody (human) 2 substances
Monoclonal antibody (humanized) 2 substances
Monoclonal antibody 1 substance
Phase III: 4

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

4 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    ADALIMUMAB; RISANKIZUMAB
    2023-506026-36-00 5 countries 2024 n=24
    Recruiting
  • Janssen - Cilag International Commercial
    USTEKINUMAB
    2022-501067-40-00 7 countries 2021 n=83
    Ended
  • Janssen - Cilag International Commercial
    GUSELKUMAB
    2023-509560-16-00 8 countries 2024 n=85
    Recruiting
  • UCB Biopharma Commercial
    BIMEKIZUMAB
    2023-508845-41-00 4 countries 2025 n=28
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Janssen - Cilag International Commercial 2 Phase III 1
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase III 1
UCB Biopharma Commercial 1 Phase III 1
New trials by year
2021
1
2024
2
2025
1
← All indication landscapes